Welcome to our dedicated page for Ani Pharmaceutic news (Ticker: ANIP), a resource for investors and traders seeking the latest updates and insights on Ani Pharmaceutic stock.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company with an active flow of corporate, clinical, and financial news. The company develops, manufactures, and commercializes therapeutics through its Rare Disease, Generics, and Brands businesses, and its communications frequently highlight progress in these areas. Investors following ANIP news can track how the Rare Disease segment, including products such as ILUVIEN and Purified Cortrophin Gel, contributes to the company’s growth alongside its generics and branded drug portfolios.
News updates for ANI often cover financial results and guidance, including quarterly earnings releases, adjusted non-GAAP metrics, and full-year outlooks. Press releases and related Form 8-K filings provide detail on net revenues by segment, the performance of key products, and management’s commentary on business trends. These disclosures also outline how Rare Disease revenues, particularly from Cortrophin Gel and ILUVIEN, compare with contributions from Generics and Brands.
ANIP news also includes clinical and medical developments, such as results from the NEW DAY clinical trial of ILUVIEN in diabetic macular edema and their presentation at major ophthalmology and retina meetings. The company reports on initiatives like the FutureVision Advisory Council, a group of retina and uveitis specialists formed to help guide its ophthalmology and retina franchise. Updates on Phase 4 trials, label transitions, and adoption trends for ILUVIEN and related products are also featured.
In addition, ANI regularly announces corporate and governance updates, including board transitions and leadership roles, as well as participation in healthcare and investor conferences hosted by organizations such as J.P. Morgan, Piper Sandler, Jefferies, H.C. Wainwright, and Morgan Stanley. These events often involve presentations or fireside chats where management discusses strategy, the transformation toward a rare disease–focused profile, and capital allocation priorities.
By monitoring ANIP news, readers can follow developments across rare disease therapeutics, generics, branded products, clinical research, and capital markets activity, all of which shape the company’s trajectory.
ANI Pharmaceuticals (NASDAQ:ANIP) announced results from the NEW DAY clinical trial evaluating ILUVIEN® for diabetic macular edema (DME) treatment. The study compared ILUVIEN to aflibercept in treatment-naïve patients.
The trial's primary endpoint of reducing supplemental aflibercept injections was not met in the intent-to-treat population (2.4 vs 2.5 injections, p=0.756). However, a secondary endpoint showed significantly longer time between treatments with ILUVIEN (185.4 vs 132.8 days, p0.001). A post-hoc analysis of patients without protocol deviations showed in supplemental injections for the ILUVIEN group (1.8 vs 2.5, p=0.029).
Safety data showed ILUVIEN was well-tolerated but had higher treatment-related adverse events (41%) compared to aflibercept (3%), mainly related to cataracts and increased intraocular pressure.
ANI Pharmaceuticals (NASDAQ:ANIP) announced its participation in the upcoming Leerink Partners Therapeutics Forum, focusing on I&I and Metabolism. The company's President and CEO, Nikhil Lalwani, will be conducting one-on-one meetings with investors during the event, which takes place on July 8, 2025, in Boston, MA.
ANI Pharmaceuticals (NASDAQ: ANIP) has announced that CEO Nikhil Lalwani will present at the upcoming 2025 Jefferies Global Healthcare Conference in New York City. The presentation is scheduled for Wednesday, June 4, 2025, at 2:35 PM ET.
Investors can access the live and archived webcast through ANI Pharmaceuticals' website at www.anipharmaceuticals.com in the Investors section under Events and Presentations. The webcast replay will be available for 60 days after the event. Interested parties can schedule one-on-one meetings with the company by contacting their Jefferies representative.
ANI Pharmaceuticals (NASDAQ: ANIP) has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ. The company's presentation is scheduled for Tuesday, May 20, 2025, at 1:30pm ET. CEO Nikhil Lalwani and CFO Stephen Carey will represent the company at the conference.
Investors can access the presentation through a live webcast on ANI's website under the Investors section. The webcast recording will remain available for 90 days after the event. One-on-one meetings with management can be arranged through meetings@hcwco.com.
ANI Pharmaceuticals (NASDAQ: ANIP) presented preclinical data on Purified Cortrophin® Gel in an experimental autoimmune uveitis (EAU) mouse model at the ARVO 2025 annual meeting. The study demonstrated that Cortrophin Gel showed a significant dose-dependent effect in suppressing EAU across all tested doses (4, 40, 160, and 400 U/kg), with the strongest suppression at 400 U/kg.
Key findings revealed that the treatment suppressed inflammatory cytokine production and reduced retinal damage caused by EAU, comparable to α-MSH treatment versus placebo. The research supports the company's understanding of Cortrophin Gel's mechanism of action and demonstrates ANI's commitment to expanding clinical research for their products.
ANI Pharmaceuticals (NASDAQ: ANIP) has scheduled its first quarter 2025 financial results announcement for Friday, May 9, 2025, before market opening. The company will host a conference call at 8:00 a.m. ET to discuss the results.
Key executives participating in the call include President and CEO Nikhil Lalwani, SVP Finance and CFO Stephen P. Carey, and Head of Rare Disease Chris Mutz. Investors can access the call via toll-free number 800-225-9448 using Conference ID 4921902.
The webcast will be available live and for replay on the company's website under the Investors section. A replay option will be accessible for two weeks by calling 800-753-8591 with access code 4921902.
ANI Pharmaceuticals (ANIP) has announced its participation in the upcoming 2025 RBC Capital Markets Ophthalmology Virtual Conference. The company's President and CEO, Nikhil Lalwani, will conduct a fireside chat during the event.
The presentation will be available through a live and archived webcast on the company's website www.anipharmaceuticals.com under the Investors section's Events and Presentations area. Interested parties can access the webcast replay for 60 days following the event.
ANI Pharmaceuticals (Nasdaq: ANIP) has announced the launch of Nitazoxanide Tablets, 500 mg, a generic version of the reference listed drug Alinia®. This launch represents another addition to ANI's portfolio of niche competition products.
The company has partnered with Biophore for this product launch, aiming to provide affordable, high-quality medicines to patients. According to IQVIA data from December 2024, the U.S. annual sales for Nitazoxanide Tablets amount to approximately $36.1 million.